Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer.
Lanickova T, Hensler M, Kasikova L, Vosahlikova S, Angelidou A, Pasulka J, Griebler H, Drozenova J, Mojzisova K, Vankerckhoven A, Laco J, Ryška A, Dundr P, Kocian R, Cibula D, Brtnicky T, Skapa P, Jacob F, Kovar M, Praznovec I, McNeish I, Halaska M, Rob L, Coosemans A, Orsulic S, Galluzzi L, Spisek R, Fucikova J. Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer. Clinical Cancer Research 2024 PMID: 39163092, DOI: 10.1158/1078-0432.ccr-24-1594.Peer-Reviewed Original ResearchHigh-grade serous ovarian carcinomaImmune checkpoint inhibitorsTertiary lymphoid structuresT cellsLymphoid structuresRecruitment of immune effector cellsMature tertiary lymphoid structuresCD8+ T cellsMetastatic ovarian cancerT-cell phenotypeFollicular T cellsSerous ovarian carcinomaSignificant survival benefitNeo-adjuvant chemotherapyImmune effector cellsIndependent patient cohortTargeted anticancer agentsCombinatorial partnersTesting chemotherapyCheckpoint inhibitorsTfh cellsCalreticulin exposureOvarian carcinomaPaclitaxel-carboplatinSyngeneic modelSerine Depletion Promotes Anti-Tumor Immunity by Activating Mitochondrial DNA-mediated cGAS-STING Signaling.
Saha S, Ghosh M, Li J, Wen A, Galluzzi L, Martinez L, Montrose D. Serine Depletion Promotes Anti-Tumor Immunity by Activating Mitochondrial DNA-mediated cGAS-STING Signaling. Cancer Research 2024 PMID: 38861367, DOI: 10.1158/0008-5472.can-23-1788.Peer-Reviewed Original ResearchAnti-tumor immunityImmune checkpoint inhibitors targeting PD-1Improved response to immune checkpoint inhibitorsCheckpoint inhibitors targeting PD-1Infiltration of immune effector cellsSuppressors of anti-tumor immunityColorectal cancerResponse to immune checkpoint inhibitorsEnhance tumor immunogenicityI interferonImmune checkpoint inhibitorsT-cell depletionCancer metabolismSerine deprivationImmune effector cellsSensitivity of tumorsType I IFN signalingAnti-neoplastic effectsImmune-enhancing effectsDisrupted metabolic pathwaysColorectal cancer cellsType I interferonCheckpoint inhibitorsIntratumoral infiltrationPD-1Immunological aspects of central neurodegeneration
Niso-Santano M, Fuentes J, Galluzzi L. Immunological aspects of central neurodegeneration. Cell Discovery 2024, 10: 41. PMID: 38594240, PMCID: PMC11004155, DOI: 10.1038/s41421-024-00666-z.Peer-Reviewed Original ResearchCentral neurodegenerationImmune effector cellsTarget immune cellsHuntington's diseaseNeuronal defectsCentral nervous systemEffector cellsImmunological dysfunctionAlzheimer's diseaseNeurodegenerative disordersImmune cellsImmunological mechanismsImmunological aspectsTherapeutic strategiesClinically relevant neuroprotective effectsNeuronal populationsNeurodegenerative conditionsNervous systemNeuroprotective effectsDiseaseNeurodegenerative syndromeTherapeutic purposesNeurodegenerationParkinson's diseaseCells